Neuroimaging Core
Neuroimaging Core
批准号:
10450021
负责人:
KEJAL KANTARCI
金额:
$83.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-09-15 至 2025-06-30
关键词:
Alzheimer&aposs DiseaseBiological MarkersBrainBrain imagingC9ORF72ClinicalClinical TrialsClinical Trials Cooperative GroupCommunitiesConfidentiality of Patient InformationConsultDataData AnalysesDementiaDiagnosisDiffusionDiseaseEnsureEthicsFrontotemporal Lobar DegenerationsFunctional Magnetic Resonance ImagingFundingFutureGenesGeneticGoalsImageImage AnalysisImaging technologyIndividualLaboratoriesLeadershipLightLongitudinal StudiesMRI ScansMagnetic Resonance ImagingMeasurementMeasuresNerve DegenerationNeurodegenerative DisordersParticipantPatientsPerfusionPharmaceutical PreparationsPreparationProceduresProcessProtocols documentationQuality ControlRecording of previous eventsResearchResearch PersonnelResearch Project GrantsResourcesRoleScanningSiteStagingStandardizationSymptomsTestingWorkcatalystclinical research sitecohortdata managementdata sharingdesigndiagnostic criteriaexperienceimage archival systemimage processingimaging biomarkerimaging studyinnovationinnovative technologiesmultimodalitymutation carrierneuroimagingneuropathologyprogramstechnology developmenttool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: NEUROIMAGING CORE
Brain imaging has taken on critical roles in dementia research, including its use for diagnosis and staging of
multiple neurodegenerative disorders and enrichment of study groups for clinical trials. In the earliest stages of
neurodegenerative disease, when symptoms have not yet developed, imaging and other biomarkers may be
the only disease indicators that can be used to quantify drug effects in clinical trials, and imaging may
ultimately guide use of approved treatments. The goal of this project is to create a neuroimaging core for the
ARTFL LEFFTDS Longitudinal FTD (ALLFTD) project. The core will ensure optimal quality and efficient,
innovative use of brain images collected for the project by designing and ensuring faithful application of a
standardized acquisition protocol across the 19 clinical sites and promoting the application of advanced
imaging technology in the FTLD field. We will design acquisition protocols that optimally utilize the scanner
capabilities for the advanced sequences at each study site and allow harmonization of images across the
study. All scans, along with the quality control information, will be made available to the public through the
Laboratory of Neuroimaging (LONI). We will provide innovative technology and resources for understanding
the contribution of MAPT, GRN or C9orf72 genes to neurodegeneration in FTLD and reliable estimates of
changes in cortical volume in asymptomatic and symptomatic mutation carriers as well as patients with
sporadic FTLD, in preparation for future clinical trials. We will provide resources for establishing the
topographic distribution of brain structural changes across the FTLD spectrum, and work with LONI to maintain
an archive of images and establish appropriate processes to ensure ethical and efficient access to the data.
The Neuroimaging Core will pursue the following aims: 1) Establish and maintain a harmonized MRI
acquisition protocol for acquisition and quality control of T1, FLAIR, T2, diffusion, ASL-perfusion, and task free
functional MRI across 19 participating sites and supply MRI scans for research projects and the research
community, while protecting patient confidentiality. 2) Operate a standardized quality control, image processing
and data analysis program. 3) Supply processed cross-sectional and longitudinal data including regional
cortical volume measurements and longitudinal change in cortical volume on serial MRIs for ALLFTD Projects
1 and 2, and also share these data with the research community. 4) Consult with ALLFTD and outside
researchers and share research tools to facilitate use of imaging data for analysis. The leaders of this
proposed neuroimaging core have extensive experience with image analysis and leadership of multicenter
imaging efforts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), which set the standard for
multisite imaging studies in dementia. This will help to ensure smooth conduct of the imaging activities for
ALLFTD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the long term impact of COVID-19 on the brain through advanced MR imaging and spectroscopy
-
批准号:10307050
-
项目类别:
-
资助金额:$72.13万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
Understanding the long term impact of COVID-19 on the brain through advanced MR imaging and spectroscopy
-
批准号:10712212
-
项目类别:
-
资助金额:$44.98万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
Understanding the long term impact of COVID-19 on the brain through advanced MR imaging and spectroscopy
-
批准号:10445068
-
项目类别:
-
资助金额:$64.42万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
NAPS2 Neuroimaging Core
-
批准号:10674049
-
项目类别:
-
资助金额:$53.77万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
NAPS2 Neuroimaging Core
-
批准号:10187087
-
项目类别:
-
资助金额:$59.91万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
Understanding the long term impact of COVID-19 on the brain through advanced MR imaging and spectroscopy
-
批准号:10649680
-
项目类别:
-
资助金额:$63.89万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
NAPS2 Neuroimaging Core
-
批准号:10457860
-
项目类别:
-
资助金额:$52.13万
-
财政年份:2021
-
负责人:KEJAL KANTARCI
-
依托单位:
Neuroimaging Core
-
批准号:10208706
-
项目类别:
-
资助金额:$83.56万
-
财政年份:2019
-
负责人:KEJAL KANTARCI
-
依托单位:
Neuroimaging Core
-
批准号:10413838
-
项目类别:
-
资助金额:$100.52万
-
财政年份:2019
-
负责人:KEJAL KANTARCI
-
依托单位:
Neuroimaging Core
-
批准号:9802931
-
项目类别:
-
资助金额:$86.44万
-
财政年份:2019
-
负责人:KEJAL KANTARCI
-
依托单位:
Neuroimaging Core
-
批准号:10228130
-
项目类别:
-
资助金额:$1.98万
-
财政年份:2019
-
负责人:KEJAL KANTARCI
-
依托单位:
Neuroimaging Core
-
批准号:10657566
-
项目类别:
-
资助金额:$61.57万
-
财政年份:2019
-
负责人:KEJAL KANTARCI
-
依托单位:
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
-
批准号:10414010
-
项目类别:
-
资助金额:$153.73万
-
财政年份:2012
-
负责人:KEJAL KANTARCI
-
依托单位:
Project 2 - Bilateral Oophorectomy on Imaging Biomarkers of Alzheimer's and Cerebrovascular Diseases
-
批准号:10414014
-
项目类别:
-
资助金额:$39.54万
-
财政年份:2012
-
负责人:KEJAL KANTARCI
-
依托单位:
Pathological basis of MRS and DTI changes in neurodegenerative dementia
-
批准号:8245476
-
项目类别:
-
资助金额:$33.36万
-
财政年份:2011
-
负责人:KEJAL KANTARCI
-
依托单位:
Pathological basis of MRS and DTI changes in neurodegenerative dementia
-
批准号:8331451
-
项目类别:
-
资助金额:$32.18万
-
财政年份:2011
-
负责人:KEJAL KANTARCI
-
依托单位:
Pathological basis of MRS and DTI changes in neurodegenerative dementia
-
批准号:8526335
-
项目类别:
-
资助金额:$30.41万
-
财政年份:2011
-
负责人:KEJAL KANTARCI
-
依托单位:
Pathological basis of MRS and DTI changes in neurodegenerative dementia
-
批准号:8856450
-
项目类别:
-
资助金额:$31.21万
-
财政年份:2011
-
负责人:KEJAL KANTARCI
-
依托单位:
Pathological basis of MRS and DTI changes in neurodegenerative dementia
-
批准号:8728096
-
项目类别:
-
资助金额:$32.17万
-
财政年份:2011
-
负责人:KEJAL KANTARCI
-
依托单位:
Mayo Clinic Building Interdisciplinary Research Careers in Women’s Health
-
批准号:10640228
-
项目类别:
-
资助金额:$74.55万
-
财政年份:2010
-
负责人:KEJAL KANTARCI
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: